

Remdesivir Key Study in Lancet April 2020 (Wang) Swept Under the Rug by Media & Fauci

"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial"

By [Dr. Paul Elias Alexander](#)

Global Research, September 23, 2022

[Alexander COVID News evidence-based medicine](#) 21 September 2022

Region: [USA](#)

Theme: [Media Disinformation](#), [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the "Translate Website" drop down menu on the top banner of our home page (Desktop version).

To receive Global Research's Daily Newsletter (selected articles), [click here](#).

Follow us on [Instagram](#) and [Twitter](#) and subscribe to our [Telegram Channel](#). Feel free to repost and share widely Global Research articles.

See highlighted passage & numbers and you can see why this study was hidden by Fauci & NIH cabal for with the flawed NIH study, it showed that Remdesivir FAILED in cutting deaths & it increased harms.

My take:

There is evidence that Fauci and NIH et al. tampered with the study protocol so that they could claim some benefit as the drug was showing ineffectiveness and safety failures. So if you look at the protocol adjustment below, they made a non patient important outcome (time to recovery), the primary outcome. These are real crooks!

Remdesivir has emerged as liver and kidney toxic and a failed EBOLA drug, failed! It was a drug in search of a disease and found one here due to Fauci and his 'standard of care'!

Remdesivir emerged as one of these ineffective and potentially harmful drugs yet was championed by the NIH/NIAID/US government as a prominent treatment. The LANCET's Wang et al. clinical trial results (below) were released on the very same morning that the US government's NIH trial results (Beigel et al., <https://www.nejm.org/doi/10.1056/NEJMoa2007764>) on remdesivir were released, and showed a failure of remdesivir and even skewed heavily towards harms.

The key Wang et al.'s findings was that in adult patients admitted to hospital for severe COVID-19, "remdesivir was not associated with statistically significant clinical benefits." Furthermore, and very alarmingly, adverse events were reported in "102 (66%) of 155 remdesivir recipients versus 50 (64%) of 78 placebo recipients. Remdesivir was stopped early because of adverse events in 18 (12%) patients versus four (5%) patients who stopped

placebo early.” In addition, the Kaplan-Meier hazard ratio was not statistically significant, reported as HR 0.73; 95% CI, 0.52 to 1.03 (final report).³

Yet the NIH highly touted and flaunted study that did not report or focus on patient-important objective outcomes and only on reduced time to recovery, was deeply flawed methodologically. The reported primary outcome was time to recovery (discharge from the hospital or hospitalization for infection-control purposes). Why was the reported primary outcome in the NIH study not mortality? Did researchers at NIH (including Dr. Anthony Fauci) use a secondary outcome such as time to recovery as the primary outcome because they were looking at the data and saw no benefit for patient-important outcomes such as mortality?

This is very serious if the NIH researchers tampered with the trial’s protocol so that they could declare efficacy yet for a secondary ‘less important’ outcome. Moreover, the legacy media and the NIH/NIAID officials completely disregarded the key findings (including strong signals of harms) from the LANCET Wang et al. trial released on the very same day. Why? When the glorified NIH study’s outcome was not patient-important and there was indication of harms: “serious adverse events were reported in 131 of the 532 patients who received remdesivir (24.6%) and in 163 of the 516 patients who received placebo (31.6%).”

SOURCE: [Wang et al.](#)

The screenshot shows a web browser displaying the Lancet article. The browser's address bar shows the URL: [thelancet.com/action/showPdf?pii=S0140-6736\(20\)2931022-9](https://www.thelancet.com/action/showPdf?pii=S0140-6736(20)2931022-9). The article title is "Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial". The authors listed are Yeming Wang*, Dingyu Zhang*, Guanhua Du*, Ronghui Du*, Jianping Zhao*, Yang Jin*, Shouzhi Fu*, Ling Gao*, Zhenshun Cheng*, Qiaofa Lu*, Yi Hu*, Guangwei Luo*, Ke Wang, Yang Lu, Huadong Li, Shuzhen Wang, Shunan Ruan, Chengqing Yang, Chunlin Mei, Yi Wang, Dan Ding, Feng Wu, Xin Tang, Xianzhi Ye, Yingchun Ye, Bing Liu, Jie Yang, Wen Yin, Aili Wang, Guohui Fan, Fei Zhou, Zhibo Liu, Xiaoying Gu, Jiuyang Xu, Lianhan Shang, Yi Zhang, Lianjun Cao, Tingting Guo, Yan Wan, Hong Qin, Yushen Jiang, Thomas Jaki, Frederick G Hayden, Peter W Horby, Bin Cao, and Chen Wang. The article is published in Lancet 2020; 395: 1569-78. The summary states: "Background No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic animal and human coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, and inhibits Middle East respiratory syndrome coronavirus, SARS-CoV-1, and SARS-CoV-2 replication in animal models." The methods section states: "Methods We did a randomised, double-blind, placebo-controlled, multicentre trial at ten hospitals in Hubei, China. Eligible patients were adults (aged ≥18 years) admitted to hospital with laboratory-confirmed SARS-CoV-2 infection, with an interval from symptom onset to enrolment of 12 days or less, oxygen saturation of 94% or less on room air or a ratio of arterial oxygen partial pressure to fractional inspired oxygen of 300 mm Hg or less, and radiologically confirmed pneumonia. Patients were randomly assigned in a 2:1 ratio to intravenous remdesivir (200 mg on day 1 followed by 100 mg on days 2–10 in single daily infusions) or the same volume of placebo infusions for 10 days. Patients were permitted concomitant use of lopinavir–ritonavir, interferons, and corticosteroids. The primary

point of a decline of two levels on a six-point ordinal scale of clinical status (from 1=discharged to 6=death) or discharged alive from hospital, whichever came first. Primary analysis was done in the intention-to-treat (ITT) population and safety analysis was done in all patients who started their assigned treatment. This trial is registered with ClinicalTrials.gov, NCT04257656.

Findings Between Feb 6, 2020, and March 12, 2020, 237 patients were enrolled and randomly assigned to a treatment group (158 to remdesivir and 79 to placebo); one patient in the placebo group who withdrew after randomisation was not included in the ITT population. Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1.23 [95% CI 0.87–1.75]). Although not statistically significant, patients receiving remdesivir had a numerically faster time to clinical improvement than those receiving placebo among patients with symptom duration of 10 days or less (hazard ratio 1.52 [0.95–2.43]). Adverse events were reported in 102 (66%) of 155 remdesivir recipients versus 50 (64%) of 78 placebo recipients. Remdesivir was stopped early because of adverse events in 18 (12%) patients versus four (5%) patients who stopped placebo early.

Interpretation In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not associated with statistically significant clinical benefits. However, the numerical reduction in time to clinical improvement in those treated earlier requires confirmation in larger studies.

Funding Chinese Academy of Medical Sciences Emergency Project of COVID-19, National Key Research and Development Program of China, the Beijing Science and Technology Project.

Copyright © 2020 Elsevier Ltd. All rights reserved.

numerically higher 28-day mortality, although there was no significant difference. Clinical improvement rates at days 14 and day 28 were also not significant different between the groups, but numerically higher in the remdesivir group.

	Remdesivir group (n=158)	Placebo group (n=78)	Difference*
Time to clinical improvement	21.0 (13.0 to 28.0)	23.0 (15.0 to 28.0)	1.23 (0.87 to 1.75) [†]
Day 28 mortality	22 (14%)	10 (13%)	1.1% (-8.1 to 10.3)
Early (≤10 days of symptom onset)	8/71 (11%)	7/47 (15%)	-3.6% (-16.2 to 8.9)
Late (>10 days of symptom onset)	12/84 (14%)	3/31 (10%)	4.6% (-8.2 to 17.4)
Clinical improvement rates			
Day 7	4 (3%)	2 (3%)	0.0% (-4.3 to 4.2)
Day 14	42 (27%)	18 (23%)	3.5% (-8.1 to 15.1)
Day 28	103 (65%)	45 (58%)	7.5% (-5.7 to 20.7)
Duration of invasive mechanical ventilation, days	7.0 (4.0 to 16.0)	15.5 (6.0 to 21.0)	-4.0 (-14.0 to 2.0)
Duration of invasive mechanical ventilation in survivors, days [‡]	19.0 (5.0 to 42.0)	42.0 (17.0 to 46.0)	-12.0 (-41.0 to 25.0)
Duration of invasive mechanical ventilation in non-survivors, days [‡]	7.0 (2.0 to 11.0)	8.0 (5.0 to 16.0)	-2.5 (-11.0 to 3.0)
Duration of oxygen support, days	19.0 (11.0 to 30.0)	21.0 (14.0 to 30.5)	-2.0 (-6.0 to 1.0)
Duration of hospital stay, days	25.0 (16.0 to 38.0)	24.0 (18.0 to 36.0)	0.0 (-4.0 to 4.0)
Time from random group assignment to discharge, days	21.0 (12.0 to 31.0)	21.0 (13.5 to 28.5)	0.0 (-3.0 to 3.0)
Time from random group assignment to death, days	25.0 (16.0 to 38.0)	24.0 (18.0 to 36.0)	0.0 (-4.0 to 4.0)

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-co...			
6 / 10	215%		
Duration of invasive mechanical ventilation in survivors, days†	19.0 (5.0 to 42.0)	42.0 (17.0 to 46.0)	-12.0 (-41.0 to 25.0)
Duration of invasive mechanical ventilation in non-survivors, days†	7.0 (2.0 to 11.0)	8.0 (5.0 to 16.0)	-2.5 (-11.0 to 3.0)
Duration of oxygen support, days	19.0 (11.0 to 30.0)	21.0 (14.0 to 30.5)	-2.0 (-6.0 to 1.0)
Duration of hospital stay, days	25.0 (16.0 to 38.0)	24.0 (18.0 to 36.0)	0.0 (-4.0 to 4.0)
Time from random group assignment to discharge, days	21.0 (12.0 to 31.0)	21.0 (13.5 to 28.5)	0.0 (-3.0 to 3.0)
Time from random group assignment to death, days	9.5 (6.0 to 18.5)	11.0 (7.0 to 18.0)	-1.0 (-7.0 to 5.0)
Six-category scale at day 7			
1—discharge (alive)	4/154 (3%)	2/77 (3%)	OR 0.69 (0.41 to 1.17)§
2—hospital admission, not requiring supplemental oxygen	21/154 (14%)	16/77 (21%)	..
3—hospital admission, requiring supplemental oxygen	87/154 (56%)	43/77 (56%)	..
4—hospital admission, requiring high-flow nasal cannula or non-invasive mechanical ventilation	26/154 (17%)	8/77 (10%)	..
5—hospital admission, requiring extracorporeal membrane oxygenation or invasive mechanical ventilation	6/154 (4%)	4/77 (5%)	..
6—death	10/154 (6%)	4/77 (5%)	..
Six-category scale at day 14			
1—discharge (alive)	39/153 (25%)	18/78 (23%)	OR 1.25 (0.76 to 2.04)§
2—hospital admission, not requiring supplemental oxygen	21/153 (14%)	10/78 (13%)	..
3—hospital admission, requiring supplemental oxygen	61/153 (40%)	28/78 (36%)	..
4—hospital admission, requiring high-flow nasal cannula or non-invasive mechanical ventilation	13/153 (8%)	8/78 (10%)	..
5—hospital admission, requiring extracorporeal membrane	4/153 (3%)	7/78 (9%)	..

thelancet.com/action/showPdf?pii=S0140-6736(20)2931022-9

8 / 10 | 215%

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-co...

5

6

7


	Remdesivir group (n=155)		Placebo group (n=78)	
	Any grade	Grade 3 or 4	Any grade	Grade 3 or 4
Adverse events (in ≥2% of patients in any treatment group)				
Any	102 (66%)	13 (8%)	50 (64%)	11 (14%)
Hypoalbuminaemia	20 (13%)	0	12 (15%)	1 (1%)
Hypokalaemia	18 (12%)	2 (1%)	11 (14%)	1 (1%)
Increased blood glucose	11 (7%)	0	6 (8%)	0
Anaemia	18 (12%)	1 (1%)	12 (15%)	2 (3%)
Rash	11 (7%)	0	2 (3%)	0
Thrombocytopenia	16 (10%)	4 (3%)	5 (6%)	3 (4%)
Increased total bilirubin	15 (10%)	1 (1%)	7 (9%)	0
Increased blood lipids	10 (6%)	0	8 (10%)	0
Increased white blood cell count	11 (7%)	0	6 (8%)	0
Hyperlipidaemia	10 (6%)	0	8 (10%)	0
Increased blood urea	10 (6%)	0	5 (6%)	0

	Remdesivir group (n=155)		Placebo group (n=78)	
	Any grade	Grade 3 or 4	Any grade	Grade 3 or 4
(Continued from previous column)				
Lung abscess	0	0		
Sepsis	0	0		
Bronchitis	0	0		
Thrombocytopenia	1 (1%)	1 (1%)		
Increased D-dimer	0	0		
Haemorrhage of lower digestive tract	1 (1%)	1 (1%)		
Ileus	0	0		
Deep vein thrombosis	1 (1%)	1 (1%)		
Acute kidney injury	1 (1%)	0		
Diabetic ketoacidosis	0	0		
Multiple organ dysfunction syndrome	1 (1%)	0		
Events leading to drug discontinuation				
Any	18 (12%)	3 (2%)		

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-co...									
ld blood lipids	10 (6%)	0	8 (10%)	0	Acute kidney injury	1 (1%)	0	0	0
ld white blood	11 (7%)	0	6 (8%)	0	Diabetic ketoacidosis	0	0	1 (1%)	1 (1%)
t					Multiple organ	1 (1%)	0	2 (3%)	0
idaemia	10 (6%)	0	8 (10%)	0	dysfunction syndrome				
ld blood urea	10 (6%)	0	5 (6%)	0	Events leading to drug discontinuation				
ld neutrophil	10 (6%)	0	4 (5%)	0	Any	18 (12%)	3 (2%)	4 (5%)	1 (1%)
e	7 (5%)	0	9 (12%)	0	Respiratory failure or	7 (5%)	1 (1%)	1 (1%)	0
nsferase					acute respiratory				
d					distress syndrome				
tion	21 (14%)	0	12 (15%)	0	Secondary infection	4 (3%)	0	7 (9%)	2 (3%)
a	8 (5%)	0	2 (3%)	0	Cardiopulmonary	3 (2%)	0	1 (1%)	0
j	5 (3%)	0	2 (3%)	0	failure				
serum	4 (3%)	0	2 (3%)	0	Nausea	1 (1%)	0	0	0
serum	4 (3%)	0	2 (3%)	0	Vomiting	1 (1%)	0	0	0
m	4 (3%)	2 (1%)	1 (1%)	0	Ileus	0	0	1 (1%)	0
Adverse events					Increased alanine	2 (1%)	1 (1%)	0	0
ry failure or	28 (18%)	9 (6%)	20 (26%)	10 (13%)	aminotransferase				
piratory	16 (10%)	4 (3%)	6 (8%)	4 (5%)	Rash	2 (1%)	0	0	0
					Poor appetite	1 (1%)	0	0	0
					Increased total	1 (1%)	0	0	0
					bilirubin				
					Acute kidney injury	1 (1%)	1 (1%)	0	0


NIH tampered with the protocol:

Remdesivir Parisa.doc [Compatibility Mode] - Word		Picture Tools		SR	
File	Home	Insert	Draw	Design	Layout
Font	Paragraph	Picture Format	Tell me what you want to do		
Clipboard	Font	Paragraph	Picture Format	Styles	Find & Replace
ClinicalTrials.gov/ct2/history/NCT04280705?A=10&B=15&C=Side-by-Side#StudyPageLog					
Changes in: Study Status , Study Description , Study Design , Arms and Interventions , Outcome Measures , Eligibility and Contacts/Locations					
<input type="checkbox"/> Show only changed modules					
March 20, 2020			April 16, 2020		
▼ Study Identification					
Unique Protocol ID: 20-0006			20-0006		
Brief Title: Adaptive COVID-19 Treatment Trial (ACTT)			Adaptive COVID-19 Treatment Trial (ACTT)		
Official Title: A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults			A Multicenter, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Adults		
Secondary IDs:					
▼ Study Status					
Record Verification: February 20, 2020			April 8, 2020		
Overall Status: Recruiting			Recruiting		
Study Start: February 21, 2020			February 21, 2020		
Primary Completion: April 1, 2023 [Anticipated]			April 1, 2023 [Anticipated]		
Study Completion: April 1, 2023 [Anticipated]			April 1, 2023 [Anticipated]		
First Submitted: February 20, 2020			February 20, 2020		
First Submitted: February 20, 2020			February 20, 2020		



*

Note to readers: Please click the share buttons above or below. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.



The Worldwide Corona Crisis, Global Coup d'Etat Against Humanity

by Michel Chossudovsky

Michel Chossudovsky reviews in detail how this insidious project “destroys people’s lives”. He provides a comprehensive analysis of everything you need to know about the “pandemic” — from the medical dimensions to the economic and social repercussions, political underpinnings, and mental and psychological impacts.

“My objective as an author is to inform people worldwide and refute the official narrative which has been used as a justification to destabilize the economic and social fabric of entire countries, followed by the imposition of the “deadly” COVID-19 “vaccine”. This crisis affects humanity in its entirety: almost 8 billion people. We stand in solidarity with our fellow

human beings and our children worldwide. Truth is a powerful instrument."

ISBN: 978-0-9879389-3-0, Year: 2022, PDF Ebook, Pages: 164, 15 Chapters

Price: \$11.50

[Purchase directly from the Global Research Online Store](#)

You may also purchase directly at [DonorBox "Worldwide Corona Crisis" Campaign Page!](#) (NOTE: User-friendly)

The original source of this article is [Alexander COVID News evidence-based medicine](#)
Copyright © [Dr. Paul Elias Alexander](#), [Alexander COVID News evidence-based medicine](#), 2022

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Dr. Paul Elias Alexander](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca